. 2009 Dec;3(6 Suppl 4):S223–S227. doi: 10.5489/cuaj.1202

Table 1.

Randomized control trials of adjuvant chemotherapy after radical cystectomy for muscle-invasive bladder cancer

Study	Chemotherapy	No. patients		Benefit	Benefit
Study	Chemotherapy	Chemotherapy	No chemotherapy	Benefit	Benefit
USC – Skinner, 1991³²	CAP	47	44	Yes	3-yr DFS: 70% vs. 46% (p = 0.001) median survival: 4.3 vs. 2.4 yrs (p = 0.006)
German – Stockle, 1992³⁴	MV(A/E)C	26	23	Yes	10-yr DFS: 41.7% vs. 17.4% (p = 0.007) 10-yr OS: 26.9% vs. 17.4% (p = 0.069)
Swiss – Studer, 1994³⁷	Cisplatin	40	37	No	5-yr OS: 57% vs. 54% (p = 0.65)
Stanford – Freiha, 1996³⁶	CMV	25	25	Yes	5-yr DFS:50% vs. 22% (p = 0.01) 5-yr OS: 54% vs. 34% (p = 0.32)

CAP = cyclophosphamide, doxorubicin and cisplatin; MV(A/E)C = methotrexate, vinblastine, doxorubicin or epirubicin, and cisplatin; CMV = cisplatin, methotrexate and vinblastine; DFS = disease-free survival; OS = overall survival.